Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Trial Details

NCT ID

NCT04614103

Phase

PHASE2

Sponsor

Iovance Biotherapeutics, Inc.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• LN-145

Locations (sample)

• Gilbert, Arizona, United States|33.35283,-111.78903
• Miami, Florida, United States|25.77427,-80.19366
• Tampa, Florida, United States|27.94752,-82.45843
• Chicago, Illinois, United States|41.85003,-87.65005
• Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

• Patients who are over 70 years of age may be allowed to enroll after discussion with the Medical Monitor.
• Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS1 genomic alterations.
• For patients who have actionable mutations (other than EGFR, ALK, or ROS1 genomic alterations), 1 additional line of therapy with the appropriate h…
• Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and plati…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.